June 06, 2024

Full Steam Ahead: Dous Technology (DOUT) and Canadian Pacific KC Forge 3-Year Pact

PRISM NextGen Tech and AI Index company, Dous Technologies (DOUT) who utilizes AI technology within railway systems and railway operator Canadian Pacific KC (CP), are poised to embark on an ambitious journey as they seal a three-year agreement. This partnership signals a significant milestone, propelling both entities forward into a future brimming with possibilities. The… [Read More]
June 06, 2024

Actelis Networks (ASNS) Announces New Orders Accelerating US Military Momentum and Exercise of Warrants For $3M Gross Proceeds

The cyber-hardened rapid deployment networking for IoT solutions company Actelis Networks, Inc. (ASNS), has announced the receipt of new orders that will supply three military bases with cyber hardened networking technology which will further its momentum with US military. These additional orders were obtained shortly after Actelis’ recent accomplishment related to its successful cybersecurity certifications… [Read More]
June 06, 2024

Market Trends Ahead of US Jobs Report: Stocks and Bonds Decline

As the market anticipates the upcoming US jobs report, stocks and bonds have seen a downturn. This report is crucial as it will influence the Federal Reserve’s future decisions. On the brink of this significant economic indicator, equity markets have pulled back from their peaks, with traders hesitant to place substantial bets prior to the… [Read More]
June 05, 2024

Surrozen Doses First Patient in Alcohol-Associated Hepatitis Study

Surrozen, Inc. (Nasdaq: SRZN), has dosed the first patient in a Phase 1b clinical study of SZN-043 in patients with severe alcohol-associated hepatitis. The open-label, multi-center clinical trial will enroll approximately 30 patients and will evaluate SZN-043, the company’s first development candidate using Surrozen’s SWEETS™ technology. Commenting on the news, Craig Parker, President and Chief… [Read More]
June 05, 2024

Structure Therapeutics Announces Positive Topline Data from Obesity Studies

Global biopharmaceutical company, Structure Therapeutics Inc. (Nasdaq: GPCR), has officially entered the obesity therapeutics race this week. The company’s shares climbed after it announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, and positive topline results from its capsule to tablet PK study. Structure said that both studies achieved their primary… [Read More]
June 05, 2024

ASCO 2024: Breakthroughs in Breast Cancer

The American Society of Clinical Oncology (ASCO) annual meeting is one of the largest gatherings of oncology professionals globally, and this year’s event showcased numerous significant breakthroughs. In breast cancer, research highlights included a study finding that most women aged 40 or younger diagnosed with early-stage breast cancer are able to have children after completing… [Read More]
June 04, 2024

FDA Fast Track for Quince Therapeutics EryDex System for Rare Disease

Shares in biotechnology company, Quince Therapeutics (Nasdaq: QNCX), climbed on Monday morning before settling up +5.66% at the close of trading, and rising an additional 3.80% after the market close. The company announced that the FDA has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia (A-T). A-T is… [Read More]